Introduction {#Sec1}
============

Abnormal renal structure or function persisting for more than 3 months, defined as chronic kidney disease (CKD), has an estimated prevalence of 3.9--12.5% globally \[[@CR1], [@CR2]\]. Diagnosis and disease staging are based on kidney function, measured by glomerular filtration rate, and patients with stage 5 disease (glomerular filtration rate \<15 mL/min/1.73 m^2^) frequently require dialysis \[[@CR3]\]. Patients with CKD are at an increased risk of numerous comorbidities, and kidney function is predictive of such complications \[[@CR4]\]. In particular, patients with CKD are at an increased risk of cardiovascular disease (CVD) compared with the general population. Although traditional risk factors for CVD, such as abnormal cholesterol profile, smoking, or physical inactivity, are frequently prevalent among patients with CKD, several large prospective studies have demonstrated that CKD itself remains an independent risk factor for CVD \[[@CR4]\].

Anemia is a common complication of CKD that becomes more prevalent with declining kidney function, and is associated with reduced quality of life (QoL) and higher morbidity and mortality \[[@CR5]--[@CR7]\]. Endogenous erythropoietin (EPO) is the hormone responsible for stimulating erythropoiesis, and is primarily produced in response to hypoxia by renal interstitial fibroblasts and is mediated by hypoxia-inducible factor \[[@CR8], [@CR9]\]. Although the pathophysiology of anemia in CKD is not fully understood, it has been postulated that transition of these erythropoietin-producing cells to myofibroblasts reduces the number of cells that can produce EPO in response to hypoxia \[[@CR10]\]. The development of recombinant human EPO (rHuEPO) has brought clinical and QoL improvements for patients with anemia. Recent evidence has shown that treatment with rHuEPO in predialysis patients with CKD may reduce mortality risk following initiation of dialysis \[[@CR11]\]. However, evidence has demonstrated that treatment with rHuEPO to achieve higher Hb levels is associated with increased of cardiovascular (CV) events \[[@CR12]--[@CR15]\]. As a result, current recommendations advocate individualized treatment to balance the potential benefits and risks for each patient \[[@CR16]\].

To achieve optimal outcomes with these treatments, the impact of CVD and anemia among patients with CKD needs to be elucidated. The purpose of this secondary analysis was to determine the real-world prevalence of CVD among patients with non-dialysis-dependent CKD (NDD-CKD), with and without comorbid anemia, and to assess the impact of these conditions on QoL and work productivity.

Methods {#Sec2}
=======

Compliance with Ethics Guidelines {#Sec3}
---------------------------------

This study was based on a market research survey adhering to the International Chamber of Commerce (ICC)/European Society for Opinion and Marketing Research (ESOMAR) international code on market and social research and therefore ethical approval was not sought.

Study Design {#Sec4}
------------

This was a multinational, cross-sectional survey of clinical practice conducted by Adelphi Real World (Bollington, UK). The Adelphi CKD Disease-Specific Programme (DSP) collected detailed information on patients, including the presence of concomitant conditions, particularly those relating to CVD, among anemic and non-anemic patients with moderate to end-stage CKD in Europe. Data for this secondary analysis were collected between June 2012 and September 2012 in France, Germany, Italy, Spain, and the UK and included patients with stage 3 \[estimated glomerular filtration rate (eGFR) ≥30 and \<60\] or 4 (eGFR ≥15 and \<30) NDD-CKD. Figure [1](#Fig1){ref-type="fig"} shows the study design, and a detailed description of the DSP methodology is provided elsewhere \[[@CR17]\]. Informed consent was provided before collection of patient-reported data. Data were collected anonymously, with respondents identified by study numbers that were matched to linked responses from physicians and their respective patients.Fig. 1Study design

Participants {#Sec5}
------------

Physicians (i.e., nephrologists and endocrinologists) who were qualified between 1971 and 2009, and who were actively involved in the drug management of patients with CKD, were eligible for participation. Nephrologists were required to enroll eight NDD-CKD patients, and endocrinologists were required to enroll 14 NDD-CKD patients (diagnosed previously or on the day of enrollment). Patients were classified as anemic if they had a physician-confirmed diagnosis of anemia, were prescribed treatment for anemia, or had a hemoglobin (Hb) level \<12 g/dL (women) or \<13 g/dL \[men; per 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline\].

Outcome Measures {#Sec6}
----------------

Physicians completed patient record forms comprising questions related to patient demographics, underlying cause of NDD-CKD, presence of anemia and other concomitant conditions, prescribed treatment, factors influencing treatment selection, and current symptoms (see Supplementary Table 1 for a full list of the terms used). As hypertension is a primary underlying cause of CKD, the association between this outcome and the presence of anemia was assessed. Patient self-completion forms were completed by the enrolled patients, and included the EuroQol EQ-5D-3L, the Kidney Disease Quality of Life (KD-QoL 36) instrument, and the Work Productivity and Activity Impairment (WPAI) questionnaire.

Statistical Analysis {#Sec7}
--------------------

Data were analyzed statistically using Stata v13.1 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP). Additional analyses were also performed using the QPSMR Reflect Database. Analyses were performed on the total patient population as well as on the following subgroups: presence of CV comorbidity, no presence of CV comorbidity, presence of anemia, and no presence of anemia.

Multivariable logistic regression analysis was used to calculate odds ratios for the presence of comorbid conditions and the underlying cause of CKD being hypertension among patients with anemia. Multivariable negative binomial regression analysis was used to calculate an incidence rate ratio for the number of comorbid conditions among patients with anemia. Regressions were adjusted for age, gender, diabetes as an underlying cause of CKD, and body mass index (BMI). Multivariable linear regression analysis was used to determine the impact of CV comorbidities on QoL and activity impairment measures in patients with anemia versus patients without anemia. Regressions were adjusted for age, gender, diabetes as an underlying cause of CKD, and BMI. For bivariate associations between patient characteristics and CV comorbidities, analysis was performed using Fisher's exact test or Chi-square test (for categorical variables), and Mann--Whitney test or Kruskal--Wallis test (for continuous variables).

Results {#Sec8}
=======

Patient Characteristics {#Sec9}
-----------------------

In total, 242 physicians (216 nephrologists and 26 endocrinologists) participated in the study and provided data for 1993 patients with stage 3--4 NDD-CKD. Patient demographics and characteristics are summarized in Table [1](#Tab1){ref-type="table"}. Most patients (1223; 61.4%) were classified as anemic \[physician-confirmed diagnosis of anemia, *n* = 636 (31.9%); prescribed treatment for anemia, 698 (35%); Hb level \<12 g/dL (women) or \<13 g/dL (men), 1097 (55%)\] and, compared with non-anemic patients, were older and more likely to be male. Approximately 35% of patients were receiving angiotensin-converting enzyme (ACE) inhibitors; the use of ACE inhibitors was not different between anemic and non-anemic patients. There were also differences between these two groups with regard to employment status, with significantly more anemic patients being unemployed or retired. Self-completion forms were completed by 867 matched patients, who provided QoL and work productivity and activity impairment data.Table 1Patient demographics and baseline characteristics by anemia statusCharacteristicsNon-anemic (*n* = 770)Anemic (*n* = 1223)Total population (*N* = 1993)*P* valueMale, *n* (%)421 (54.7)767 (62.7)1188 (59.6)\<0.001Age (years)62.5 (14.8)66.5 (14.5)64.9 (14.7)\<0.001BMI (kg/m^2^)27.1 (5.0)26.7 (4.9)26.9 (5.0)0.209Years since CKD diagnosis0.93 (1.3)0.94 (0.98)0.94 (1.1)0.17Years since anemia diagnosis--1.7 (3.6)----Systolic blood pressure (mmHg)138.1 (16.6)138.5 (17.5)138.4 (17.2)0.554Diastolic blood pressure (mmHg)78.0 (11.6)77.6 (11.8)77.7 (11.8)0.735Smoking status, *n* (%)0.633 Smoker82 (11.8)129 (11.7)211 (11.8) Ex-smoker240 (34.4)402 (36.6)642 (35.7) Never smoked375 (53.8)568 (51.7)943 (52.5)Years smoked\
(current smokers)24.6 (12.5)28.4 (14.5)26.9 (13.8)0.065Daily cigarettes\
(current smokers)13.5 (6.3)14.6 (7.9)14.2 (7.3)0.438Employment status, *n* (%)\<0.001 Employed257 (34.2)207 (17.5)464 (24.0) Unemployed40 (5.3)87 (7.3)127 (6.6) Retired366 (48.7)744 (62.8)1110 (57.4) Other88 (11.7)146 (12.3)234 (12.1)Living circumstances, *n* (%)0.012 Alone146 (19.7)228 (19.5)374 (19.5) With friends, spouse, partner, or other family572 (77.1)878 (74.9)1450 (75.8) Nursing home, sheltered housing, or homeless14 (1.9)55 (4.7)69 (3.6) Other10 (1.4)11 (0.9)21 (1.1)Number of concomitant CV conditions\*0.95 (1.1)1.27 (1.3)1.15 (1.2)\<0.001Underlying cause of CKD: hypertension392 (51.4)719 (59.4)1111 (56.3)\<0.001Underlying cause of CKD: diabetes336 (44.0)512 (42.3)848 (43.0)0.455Concomitant conditions, *n* (%) Dyslipidemia316 (41.6)536 (44.3)852 (43.3)0.243 Coronary heart disease109 (14.4)270 (22.3)379 (19.3)\<0.001 Peripheral arterial disease57 (7.5)207 (17.1)264 (13.4)\<0.001 Heart failure52 (6.9)136 (11.2)188 (9.6)0.001 Arrhythmia53 (7.0)116 (9.6)169 (8.6)0.047 Heart attack/MI/UA35 (4.6)83 (6.9)118 (6.0)0.041 Other CV43 (5.7)73 (6.0)116 (5.9)0.769 CVA/TIA32 (4.2)76 (6.3)108 (5.5)0.053 Stroke22 (2.9)44 (3.6)66 (3.4)0.441Concomitant treatment, *n* (%)0.598 ACE inhibitor271 (35.2)445 (36.4)716 (35.9)Data are presented as mean (SD) unless otherwise noted. *P* values compare anemic and non-anemic patients and are calculated from Fisher's exact test, Chi-squared test (categorical variables), a Mann--Whitney test or Kruskal--Wallis test (continuous variables), or a Mann--Whitney test (\*only)*ACE* angiotensin-converting enzyme, *BMI* body mass index, *CKD* chronic kidney disease, *CV* cardiovascular, *CVA* cerebrovascular accident, *CVD* cardiovascular disease, *MI* myocardial infarction, *SD* standard deviation, *TIA* transient ischemic attack, *UA* unstable angina

Relationship Between Cardiovascular Disease and Anemia {#Sec10}
------------------------------------------------------

On the basis of patient record forms, the most frequent concomitant conditions experienced by both anemic and non-anemic patients were CV-related, followed by metabolic diseases and mental health disorders (Fig. [2](#Fig2){ref-type="fig"}). Patients with anemia had more CV-related concomitant conditions than non-anemic patients (non-anemic, 0.95; anemic, 1.27; *P* \< 0.001). Hypertension was the underlying cause of CKD in 51.4% of the total population, and was more prevalent as the underlying cause among anemic patients (59.4%) compared with nonanemic patients (56.3%) (Table [1](#Tab1){ref-type="table"}). Of the CV-related comorbidities, dyslipidemia was the most common condition, and was prevalent in 44.3% and 41.6% of anemic and non-anemic patients, respectively. Compared with non-anemic patients, those with anemia had a significantly higher prevalence of arrhythmia, heart attack/myocardial infarction/unstable angina, coronary heart disease, heart failure, and peripheral arterial disease (Table [1](#Tab1){ref-type="table"}). The complete results of logistic regression for concomitant conditions, using the non-anemic cohort as a reference category, are shown in Table [2](#Tab2){ref-type="table"}. Anemic status remained independently associated with the likelihood of coronary heart disease (odds ratio, 1.41; 95% CI 1.03--1.94; *P* = 0.032) and peripheral arterial disease (odds ratio, 1.80; 95% CI 1.25--2.60; *P* = 0.002). Negative binomial modelling demonstrated that anemia was associated with a greater number of concomitant CV conditions (incidence rate ratio, 1.17; 95% CI 1.03--1.31; *P* = 0.012).Fig. 2Concomitant conditions experienced by anemic and non-anemic NDD-CKD patients. \**P* \< 0.001; ^†^ *P* = 0.005; ^‡^ *P* = 0.008 Table 2Association between anemia and concomitant CVD conditionsOutcomePresence of anemia*P* valueUnderlying cause of CKD: hypertension1.19\
(0.92, 1.53)0.190Stroke0.98\
(0.55, 1.76)0.951CVA/TIA1.06\
(0.63, 1.78)0.818Dyslipidemia1.04\
(0.81, 1.33)0.760Arrhythmia1.09\
(0.72, 1.65)0.676Heart attack/MI/unstable angina1.27\
(0.83, 1.95)0.270Coronary heart disease1.41\
(1.03, 1.94)0.032Heart failure1.43\
(0.96, 2.14)0.080Peripheral arterial disease1.80\
(1.25, 2.60)0.002Other CV1.12\
(0.53, 2.33)0.768Number of concomitant CV conditions\*1.17\
(1.03, 1.31)0.012Values are odds ratios (95% confidence interval) of anemia increasing the likelihood of each outcome (logistic models) or (\*) incidence rate ratios (negative binomial models). Dependent variables are the concomitant conditions listed or (\*) number of concomitant conditions; independent variable is anemia status. Reference category is the non-anemic group. Regressions are adjusted for age, gender, stage/dialysis status, diabetes as an underlying cause of CKD, and BMI*BMI* body mass index, *CKD* chronic kidney disease, *CVA* cerebrovascular accident, *TIA* transient ischemic attack

Cardiovascular Disease, Anemia, and Quality of Life {#Sec11}
---------------------------------------------------

In anemic patients, multiple linear regression analysis revealed that the presence of CV conditions was significantly associated with lower QoL, as measured by EQ-5D visual analog scale (VAS) (coefficient, −5.68; 95% CI −10.76 to −0.61; *P* = 0.028), KD-QoL 36: effects of kidney disease (coefficient, −6.09; 95% CI −11.23 to −0.95; *P* = 0.021), and KD-QoL 36: SF-12 physical health composite (coefficient, −2.38; 95% CI −4.72 to −0.05; *P* = 0.046) (Table [3](#Tab3){ref-type="table"}). No associations between the presence of CV conditions and QoL were observed in non-anemic patients or in the total population. Scores for all QoL measures, stratified by anemic status and presence of CV conditions, are presented in Supplementary Table 2.Table 3Association between CV conditions and quality of life by anemic statusCharacteristicsNon-anemic\
(*n* = 336)Anemic\
(*n* = 531)Total population\
(*N* = 867)EQ-5D health index0.00 (−0.06 to 0.06)\
*P* = 0.946−0.06 (−0.12 to 0.00)\
*P* = 0.068−0.04 (−0.09 to 0.01)\
*P* = 0.093EQ-5D VAS1.10 (−4.00 to 6.19)\
*P* = 0.670−5.68 (−10.76 to −0.61)\
*P* = 0.028−3.43 (−7.39 to −0.54)\
*P* = 0.090KD-QoL 36: symptoms/problems0.69 (−3.72 to 5.09)\
*P* = 0.758−3.21 (−8.12 to 1.70)\
*P* = 0.198−2.21 (−5.81 to 1.39)\
*P* = 0.228KD-QoL 36: effects of kidney disease1.22 (−4.13 to 6.57)\
*P* = 0.652−6.09 (−11.23 to −0.95)\
*P* = 0.021−3.80 (−7.86 to 0.26)\
*P* = 0.066KD-QoL 36: burden of kidney disease4.50 (−2.43 to 11.44)\
*P* = 0.201−4.48 (−10.89 to 1.93)\
*P* = 0.169−1.63 (−7.05 to 3.79)\
*P* = 0.554KD-QoL 36: SF-12 physical health composite−0.47 (−3.25 to 2.31)\
*P* = 0.737−2.38 (−4.72 to −0.05)\
*P* = 0.046−1.83 (−3.83 to 0.17)\
*P* = 0.073KD-QoL 36: SF-12 mental health composite1.87 (−0.54 to 4.28)\
*P* = 0.127−1.49 (−3.83 to 0.84)\
*P* = 0.208−0.26 (−1.96 to 1.44)\
*P* = 0.761Values are coefficients (95% confidence interval) from ordinary least squares multiple linear regression models. Reference category is those without CV conditions. Regressions are adjusted for age, gender, stage/dialysis status, diabetes as an underlying cause of CKD, and BMI*BMI* body mass index, *CKD* chronic kidney disease, *CV* cardiovascular, *KD-QoL 36* kidney disease quality of life, *VAS* visual analog scale

Cardiovascular Disease, Anemia, and Work Productivity and Activity Impairment {#Sec12}
-----------------------------------------------------------------------------

In anemic patients only, multiple linear regression analysis revealed that the presence of CV conditions was significantly associated with WPAI: activity impairment (coefficient, 8.04; 95% CI 0.70--15.39; *P* = 0.032) (Table [4](#Tab4){ref-type="table"}). No significant associations between the presence of CV conditions and work activity impairment were observed in non-anemic patients or in the total population. Scores for all WPAI measures, stratified by anemic status and presence of CV conditions, are presented in Supplementary Table 3.Table 4Association between CV conditions and work productivity and activity impairmentCharacteristicsNon-anemic\
(*n* = 336)Anemic\
(*n* = 531)Total population\
(*N* = 867)WPAI: percentage of work time missed−1.42 (−4.74 to 1.90)\
*P* = 0.3936.81 (−0.39 to 14.02)\
*P* = 0.0632.41 (−1.21 to 6.03)\
*P* = 0.189WPAI: percentage of work time impaired−4.22 (−12.50 to 4.07)\
*P* = 0.3126.81 (−2.31 to 15.92)\
*P* = 0.1402.19 (−4.78 to 9.15)\
*P* = 0.533WPAI: overall work impairment−5.99 (−15.43 to 3.46)\
*P* = 0.2098.53 (−3.28 to 20.33)\
*P* = 0.1532.04 (−5.65 to 9.72)\
*P* = 0.599WPAI: activity impairment−2.57 (−9.50 to 4.35)\
*P* = 0.4638.04 (0.70 to 15.39)\
*P* = 0.0324.31 (−1.35 to 9.97)\
*P* = 0.135Values are coefficients (95% confidence interval) from ordinary least-squares multiple linear regression models. Reference category is those without CV conditions. Regressions are adjusted for age, gender, stage/dialysis status, diabetes as an underlying cause of CKD, and BMI*BMI* body mass index, *CKD* chronic kidney disease, *CV* cardiovascular, *WPAI* work productivity and activity impairment

Discussion {#Sec13}
==========

This analysis of multinational, cross-sectional data representing real-world clinical practice confirms a high prevalence of physician-assessed anemia in patients with stage 3--4 NDD-CKD. In this population, anemia was associated with a higher number of concomitant conditions, in particular CVD. The presence of concomitant CVD and anemia was associated with reduced QoL measures and work productivity and greater activity impairment.

Previous studies have shown that there is a direct relationship between older age and an increased prevalence in anemia, irrespective of renal function \[[@CR18], [@CR19]\]. Similar to these studies, we found that patients with anemia were significantly older than those without anemia. A US National Health and Nutrition Examination Survey (NHANES) study found that, in patients with CKD, CVD correlated with CKD severity as well as with age \[[@CR20]\]. A UK prospective, observational study in patients with CKD, followed up from the time of diagnosis of diabetes, found that CVD was the most common cause of mortality, and that CVD risk increased with progression of nephropathy from 0.7% in non-nephrotic patients to 12.1% in patients with the most advanced stage of nephropathy (i.e., elevated plasma creatinine or renal replacement therapy). Additionally, the proportion of CV-related deaths increased from 51% in non-nephrotic patients to 75% in patients with advanced nephropathy \[[@CR21]\]. It has been suggested that the pathophysiologic mechanisms underlying CKD and CVD may mutually amplify each other, therefore causing a greater impact on patient health \[[@CR22]\]. Furthermore, as demonstrated by de Silva et al. \[[@CR23]\], a high proportion of patients with CVD have both CKD and anemia, and these two conditions are closely related. In this population, anemia and CKD are associated with increased all-cause mortality, and this risk has been shown to be additive \[[@CR22], [@CR23]\].

A recent study demonstrated that anemia in CKD is associated with increased disease burden and activity impairment as well as with diminished QoL \[[@CR24]\]. Significantly lower QoL has previously been demonstrated in patients with CKD compared with matched controls, even in early stages of disease, with scores deteriorating at more advanced CKD stages \[[@CR25]\]. The current study goes further and shows that, in a CKD population, the presence of both anemia and CVD is associated with a lower QoL, as measured by several QoL measures.

This study has limitations that should be considered when interpreting the results. Selection bias may have occurred as a result of recruiting a selected group of physicians to enroll patients. In addition, because inclusion depended on the patient attending a clinic, patients who attend more frequently were more likely to be enrolled. Although consecutive sampling provides representation of a real-world consulting CKD population, this design may limit the generalizability of the results. Furthermore, less than half of the enrolled patients completed the patient self-completion form that captured QoL data. As participants could have pre-existing CKD, no standardized diagnostic procedure for CKD was used, and adjustments for kidney function were not made. In addition, although the cutoff criteria for anemia were defined in accordance with KDIGO guidelines, patients receiving anemia treatment, or who had a physician-confirmed diagnosis of anemia, were classified as being anemic without further testing. Another limitation of this study is that there are no data on iron parameters (i.e., ferritin, transferrin saturation). It is well known that iron is a crucial element that reduces platelet count and also improves mitochondrial and cardiac function \[[@CR26], [@CR27]\]. Understanding more about iron stores can reveal meaningful pathways in the relationship between anemia and CVD in patients with CKD. Lastly, as this was an observational study of data obtained from existing medical records, the non-interventional and cross-sectional design do not allow for any cause and effect inferences to be made.

Conclusions {#Sec14}
===========

In this cross-sectional survey of clinical practice, a high prevalence of anemia was found in patients with CKD. CVD comorbidities were more common among anemic patients compared with non-anemic patients, and were associated with significant decreases in QoL indicators.
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